FDA APPROVALS IN SECOND HALF 1994 COULD FEATURE CARDIOVASCULAR DRUGS INCLUDING CENTOCOR's REOPRO; MID-YEAR NDA COUNT DOUBLES FROM 1993
Executive Summary
FDA's new drug and biological approvals in the second half of 1994 could feature cardiovascular agents, with Centocor's ReoPro appearing likely to be one of the crop.